Search research articles
Contact Us
Filters
Showing results (141-150 of 268) with videos related to
Page
of 27
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 31, 2019
A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer
James J Harding, Andrew X Zhu, Todd M Bauer, et al.
JTO Clinical and Research Reports
|
July 21, 2025
A Phase II Study of Cabozantinib in Patients With <i>MET</i>-Altered Lung Cancers
Guilherme Harada, Fernando C Santini, Clare J Wilhelm, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 2, 2024
Durability of Response With Selpercatinib in Patients With <i>RET</i>-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001
Lori J Wirth, Marcia S Brose, Vivek Subbiah, et al.
Cancers
|
November 7, 2020
Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis
Antoine Italiano, Shivani Nanda, Andrew Briggs, et al.
Current Problems in Cancer
|
April 18, 2021
Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib
Shivaani Kummar, Jordan Berlin, Leo Mascarenhas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 18, 2015
A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer
Alexander Drilon, Romel Somwar, Jacob P Wagner, et al.
Future Oncology (London, England)
|
November 5, 2020
Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated <i>RET</i> positive non-small-cell lung cancer
Benjamin J Solomon, Cai Cun Zhou, Alexander Drilon, et al.
Cold Spring Harbor Molecular Case Studies
|
April 3, 2019
Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with <i>KRAS</i> G12D-mutant lung cancers
Alexander Drilon, Adam J Schoenfeld, Kathryn C Arbour, et al.
The American Journal of Surgical Pathology
|
March 20, 2018
NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma
Sarah Chiang, Paolo Cotzia, David M Hyman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 25, 2018
Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer
Ken Suzawa, Michael Offin, Daniel Lu, et al.
Page
of 27
Search research articles
Search
Showing results (141-150 of 268) with videos related to
Sort By:
Page
of 27
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 31, 2019
A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer
James J Harding, Andrew X Zhu, Todd M Bauer, et al.
JTO Clinical and Research Reports
|
July 21, 2025
A Phase II Study of Cabozantinib in Patients With <i>MET</i>-Altered Lung Cancers
Guilherme Harada, Fernando C Santini, Clare J Wilhelm, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 2, 2024
Durability of Response With Selpercatinib in Patients With <i>RET</i>-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001
Lori J Wirth, Marcia S Brose, Vivek Subbiah, et al.
Cancers
|
November 7, 2020
Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis
Antoine Italiano, Shivani Nanda, Andrew Briggs, et al.
Current Problems in Cancer
|
April 18, 2021
Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib
Shivaani Kummar, Jordan Berlin, Leo Mascarenhas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 18, 2015
A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer
Alexander Drilon, Romel Somwar, Jacob P Wagner, et al.
Future Oncology (London, England)
|
November 5, 2020
Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated <i>RET</i> positive non-small-cell lung cancer
Benjamin J Solomon, Cai Cun Zhou, Alexander Drilon, et al.
Cold Spring Harbor Molecular Case Studies
|
April 3, 2019
Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with <i>KRAS</i> G12D-mutant lung cancers
Alexander Drilon, Adam J Schoenfeld, Kathryn C Arbour, et al.
The American Journal of Surgical Pathology
|
March 20, 2018
NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma
Sarah Chiang, Paolo Cotzia, David M Hyman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 25, 2018
Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer
Ken Suzawa, Michael Offin, Daniel Lu, et al.
Page
of 27